Dr. Jakubowiak on Minimal Residual Disease in Multiple Myeloma

Andrzej Jakubowiak, MD, PhD
Published: Wednesday, Sep 14, 2016



Andrzej Jakubowiak, MD, PhD, professor of Medicine, director, Myeloma Program, University of Chicago Medicine, discusses minimal residual disease (MRD) in multiple myeloma.

The combination of the proteasome inhibitor carfilzomib (Kyprolis) with lenalidomide (Revlimid) and dexamethasone demonstrated significant efficacy in a phase I and II studies in relapsed multiple myeloma.

Disease assessments were made with the use of the International Myeloma Working Group Uniform Response Criteria, with minimal response defined according to European Society for Blood and Marrow Transplantation criteria.
SELECTED
LANGUAGE


Andrzej Jakubowiak, MD, PhD, professor of Medicine, director, Myeloma Program, University of Chicago Medicine, discusses minimal residual disease (MRD) in multiple myeloma.

The combination of the proteasome inhibitor carfilzomib (Kyprolis) with lenalidomide (Revlimid) and dexamethasone demonstrated significant efficacy in a phase I and II studies in relapsed multiple myeloma.

Disease assessments were made with the use of the International Myeloma Working Group Uniform Response Criteria, with minimal response defined according to European Society for Blood and Marrow Transplantation criteria.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication
x